Puma Biotechnology director to sell 5,000 shares

A PUMA BIOTECHNOLOGY director filed a Rule 144 notice to sell 5,000 common shares worth about $45,500.

Rhea-AI Filing Summary

PUMA BIOTECHNOLOGY, INC. (PBYI) has a notice of proposed sale under Rule 144 by director Troy Edward Wilson. The filing covers a planned sale of 5,000 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of $45,500.00, and a proposed sale date of September 14, 2026. The shares relate to restricted stock vesting recorded as compensation from June 11, 2025.

Key Figures

Shares to be sold: 5,000 shares Aggregate market value: $45,500.00 Proposed sale date: September 14, 2026 +1 more

4 metrics

Shares to be sold 5,000 shares Common stock covered by Rule 144 notice for Troy Edward Wilson

Aggregate market value $45,500.00 Reported value of 5,000 common shares to be sold

Proposed sale date September 14, 2026 Date listed for proposed Rule 144 sale of common stock

Acquisition date of shares June 11, 2025 Restricted stock vesting date for the 5,000 shares

Key Terms

Rule 144, Restricted Stock Vesting, attorney-in-fact

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Vesting financial

"Common | 06/11/2025 | Restricted Stock Vesting | Issuer"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

attorney-in-fact regulatory

"as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for PBYI disclose?

It discloses that director Troy Edward Wilson has filed a Rule 144 notice for a proposed sale of 5,000 shares of PUMA BIOTECHNOLOGY, INC. common stock, with an aggregate market value of $45,500.00, to be sold through Fidelity Brokerage Services LLC.

How many PBYI shares are covered by this Rule 144 notice?

The notice covers a proposed sale of 5,000 shares of PUMA BIOTECHNOLOGY, INC. common stock, as listed in the securities information and securities-to-be-sold sections.

What is the approximate value of the PBYI shares to be sold?

The aggregate market value of the 5,000 shares of PUMA BIOTECHNOLOGY, INC. common stock covered by the notice is listed as $45,500.00.

When are the PBYI shares proposed to be sold under this Form 144?

The proposed date of sale for the 5,000 shares of PUMA BIOTECHNOLOGY, INC. common stock is listed as September 14, 2026.

How and when did the insider acquire the PBYI shares in this filing?

The shares are reported under “Securities To Be Sold” as common stock acquired through Restricted Stock Vesting from the issuer, with an acquisition date of June 11, 2025, and characterized as Compensation.

Who is the broker for the PBYI Form 144 sale?

The proposed sale of 5,000 PUMA BIOTECHNOLOGY, INC. common shares is listed with Fidelity Brokerage Services LLC as the broker, including its Smithfield, Rhode Island address.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 12:02 PM Accepted by SEC EDGAR 09/14/2026 - 12:01 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001589597
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	PUMA BIOTECHNOLOGY, INC.
SEC File Number	001-35703
Address of Issuer	10880 WILSHIRE BLVD. SUITE 1700 LOS ANGELES CALIFORNIA 90024
Phone	(424) 248-6500
Name of Person for Whose Account the Securities are To Be Sold	WILSON TROY EDWARD
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	5000	45500.00	51620066	09/14/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/11/2025	Restricted Stock Vesting	Issuer			5000	06/11/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/14/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/15/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Troy Wilson
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)